354 related articles for article (PubMed ID: 37122754)
1. Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.
Rao DY; Huang DF; Si MY; Lu H; Tang ZX; Zhang ZX
Front Immunol; 2023; 14():1142539. PubMed ID: 37122754
[TBL] [Abstract][Full Text] [Related]
2. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
3. Exosomal epidermal growth factor receptor is involved in HPV-16 E7-induced epithelial-mesenchymal transition of non-small cell lung cancer cells: A driver of signaling in vivo.
Zhou Z; Wu X; Zhan R; Li X; Cheng D; Chen L; Wang T; Yu H; Zhang G; Tang X
Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 36224722
[TBL] [Abstract][Full Text] [Related]
4. Exosomes: a new perspective in EGFR-mutated lung cancer.
Jouida A; McCarthy C; Fabre A; Keane MP
Cancer Metastasis Rev; 2021 Jun; 40(2):589-601. PubMed ID: 33855679
[TBL] [Abstract][Full Text] [Related]
5. [Research Progress of the Role of EMT in EGFR-TKIs Resistance
of Non-small Cell Lung Cancer].
Yu L; Huang S; Lv W; He Z; Hu J
Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):907-911. PubMed ID: 30591098
[TBL] [Abstract][Full Text] [Related]
6. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.
Bronte G; Bravaccini S; Bronte E; Burgio MA; Rolfo C; Delmonte A; Crinò L
Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1735-1746. PubMed ID: 29671943
[TBL] [Abstract][Full Text] [Related]
8. Exosomes from
Jouida A; O'Callaghan M; Mc Carthy C; Fabre A; Nadarajan P; Keane MP
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954442
[TBL] [Abstract][Full Text] [Related]
9. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.
Lobb RJ; van Amerongen R; Wiegmans A; Ham S; Larsen JE; Möller A
Int J Cancer; 2017 Aug; 141(3):614-620. PubMed ID: 28445609
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
11. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
[TBL] [Abstract][Full Text] [Related]
12. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
Lawal B; Wu ATH; Huang HS
Front Immunol; 2022; 13():872470. PubMed ID: 35655775
[TBL] [Abstract][Full Text] [Related]
13. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.
Takenaka T; Nakai S; Katayama M; Hirano M; Ueno N; Noguchi K; Takatani-Nakase T; Fujii I; Kobayashi SS; Nakase I
Int J Pharm; 2019 Dec; 572():118762. PubMed ID: 31610280
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
[TBL] [Abstract][Full Text] [Related]
15.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
16. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
17. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
18. Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.
Zhou D; Xia Z; Xie M; Gao Y; Yu Q; He B
Hum Cell; 2021 Sep; 34(5):1478-1489. PubMed ID: 34244990
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases.
Jiang J; Lu Y; Chu J; Zhang X; Xu C; Liu S; Wan Z; Wang J; Zhang L; Liu K; Liu Z; Yang A; Ren X; Zhang R
J Nanobiotechnology; 2024 Apr; 22(1):159. PubMed ID: 38589859
[TBL] [Abstract][Full Text] [Related]
20. Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).
Okuma Y; Morikawa K; Tanaka H; Yokoyama T; Itani H; Horiuchi K; Nakagawa H; Takahashi N; Bessho A; Soejima K; Kishi K; Togashi A; Kanai Y; Ueda K; Horimoto K; Matsutani N; Seki N
Thorac Cancer; 2019 Feb; 10(2):395-400. PubMed ID: 30536780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
